- Conditions
- Coronary Artery Disease, Atherosclerosis, Stent Placement
- Interventions
- Dual Antiplatelet (DAPT) Therapy, The Synergy® stent
- Drug · Device
- Lead sponsor
- HonorHealth Research Institute
- Other
- Eligibility
- 75 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Boston, Massachusetts • New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 121–144
of 176
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Obstructive Sleep Apnea
- Interventions
- Aspirin Resistance testing
- Other
- Lead sponsor
- Danbury Hospital
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Danbury, Connecticut
- Conditions
- Bradycardia, Arrhythmias
- Interventions
- Atropine
- Drug
- Lead sponsor
- State University of New York at Buffalo
- Other
- Eligibility
- 1 Day to 2 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Community-acquired Pneumonia, Influenza, COVID-19
- Interventions
- Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
- Drug · Other · Biological + 1 more
- Lead sponsor
- UMC Utrecht
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 11
- States / cities
- Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
- Conditions
- Ischemic Stroke
- Interventions
- Aspirin, tinzaparin sodium, eptifibatide
- Drug
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2011
- U.S. locations
- 3
- States / cities
- Washington D.C., District of Columbia • Bethesda, Maryland
- Conditions
- Acute Coronary Syndrome, Myocardial Infarction, Myocardial Ischemia, Unstable Angina
- Interventions
- Rivaroxaban 2.5 mg, Rivaroxaban 5 mg, Placebo, Standard of care
- Drug
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15,526 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 73
- States / cities
- Birmingham, Alabama • Geneva, Alabama • Mobile, Alabama + 70 more
- Conditions
- Microscopic Colitis, Diarrhea
- Interventions
- Mesalamine
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Colitis, Ulcerative
- Interventions
- Treatment Algorithm A, Treatment Algorithm B, Treatment Algorithm C
- Biological
- Lead sponsor
- Alimentiv Inc.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 672 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 5
- States / cities
- Ypsilanti, Michigan • New York, New York • Asheville, North Carolina + 1 more
- Conditions
- Acute Coronary Syndromes
- Interventions
- Apixaban, vitamin K antagonist, Acetylsalicylic acid, Acetylsalicylic acid placebo
- Drug · Other
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 95 Years
- Enrollment
- 4,614 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 143
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 125 more
- Conditions
- Ulcerative Colitis
- Interventions
- Not listed
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Dense Deposit Disease, Membranoproliferative Glomerulonephritis
- Interventions
- Eculizumab
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 2
- States / cities
- New York, New York
- Conditions
- Ulcerative Colitis
- Interventions
- mesalamine
- Drug
- Lead sponsor
- James Lewis
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 119 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 8
- States / cities
- Naples, Florida • Winter Park, Florida • Atlanta, Georgia + 5 more
- Conditions
- Hermanski-Pudlak Syndrome, Colitis, Cytokines, Lymphocytes, Drug Evaluation
- Interventions
- Mesalamine, Infliximab, Corticosteroids, 6-Mercaptopurine, Tacrolimus, Adalimumab
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Healthy Volunteers
- Interventions
- Aspirin, BMS-986177, Placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Coronary Artery Disease
- Interventions
- PROMUS Element Plus Coronary Stent System, Aspirin, P2Y12 antagonist
- Device · Drug
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- Not listed
- Enrollment
- 2,681 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 52
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Jonesboro, Arkansas + 44 more
- Conditions
- Ulcerative Colitis
- Interventions
- MMX Mesalamine/Mesalazine (Low Dose), MMX Mesalamine/Mesalazine (High Dose)
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 5 Years to 17 Years
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 9
- States / cities
- Baltimore, Maryland • Boston, Massachusetts • Newton, Massachusetts + 5 more
- Conditions
- Atrial Fibrillation, Stroke
- Interventions
- Apixaban, aspirin
- Drug
- Lead sponsor
- Population Health Research Institute
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 4,012 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 23
- States / cities
- Mesa, Arizona • Little Rock, Arkansas • Larkspur, California + 20 more
- Conditions
- Ulcerative Colitis
- Interventions
- Budesonide MMX®, Placebo, 5-ASA
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 510 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 39
- States / cities
- Anaheim, California • Lakewood, California • San Diego, California + 36 more
- Conditions
- Colitis Ulcerative, Crohn Disease
- Interventions
- Not listed
- Lead sponsor
- Harvard School of Public Health (HSPH)
- Other
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2018
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Ulcerative Colitis
- Interventions
- LT-02, LT-02 Placebo
- Drug
- Lead sponsor
- Prometheus Laboratories
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 45
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Chula Vista, California + 39 more
- Conditions
- Procedural Anxiety, Procedural Pain
- Interventions
- Remimazolam 20 MG [Byfavo]
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Chronic Kidney Disease
- Interventions
- Aspirin, Clopidogrel
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 21 Years to 90 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Shoulder Pain
- Interventions
- Recruitment manouver
- Procedure
- Lead sponsor
- Phelps, Paul, M.D.
- Individual
- Eligibility
- 15 Years to 65 Years · Female only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 1
- States / cities
- Wildomar, California
- Conditions
- Atrial Fibrillation, Device Related Thrombus, Left Atrial Appendage Thrombosis, Watchman LAA Closure Device
- Interventions
- Dabigatran Etexilate Oral Capsule
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee